immunoglobulin G

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

3 competitors in Dystrophic Epidermolysis Bullosa

#DrugCompanyPhaseTrials

1

immunoglobulin G

CSL Behring

Phase 2

12

AGLE-102

AAegle Therapeutics

Phase 2

13

ALLO-ASC-SHEET

AAnterogen Co., Ltd.

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Kawasaki Disease2 trials

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Completed·GGreen Cross Corporation·Phase 4·NCT01524939·45 enrolled

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Completed·GGreen Cross Corporation·Phase 4·NCT04003844·45 enrolled

ESS1 trial

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Completed·Roche·Phase 1·NCT07025577·82 enrolled

Septic Shock1 trial

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Terminated·GGreen Cross Corporation·Phase 3·NCT01315496·214 enrolled

Autoimmune Encephalitis1 trial

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Completed·GGreen Cross Corporation·Phase 2·NCT04175522·23 enrolled

Treatment1 trial

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

Terminated·UUniversity of Pittsburgh·Phase 4·NCT00177970·14 enrolled

2 more indications

Immunodeficiency1 trial

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Completed·CSL Behring·Phase 3·NCT00680446·41 enrolled

Dystrophic epidermolysis bullosa1 trial

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Recruiting·MM. Peter Marinkovich·Phase 1/2·NCT06834035·8 enrolled

Details

Drug Info

Related News